GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1?? (HIF-1??) pathways

Medicine and Dentistry

• Thyroid Carcinoma 100%
• Carcinoma Cell 71%
• Phosphatase 57%
• Tensin 57%
• Anoxia 42%
• Thyroid Follicular Carcinoma 42%
• Lung 28%
• Vasculotropin 28%
• Enhanced Green Fluorescent Protein 28%
• In Vitro 14%
• Antiproliferative Activity 14%
• Xenograft 14%
• Thyroid Gland 14%
• Secretion (Process) 14%
• Tumor Progression 14%
• Cell Line 14%
• Transcription Factor 14%
• Wound 14%
• Lung Metastasis 14%
• Null Cell 14%
• Phosphoinositide 3-Kinase Inhibitor 14%
• Glucose Transporter 1 14%
• Thyroid Carcinoma Cell Line 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Thyroid Carcinoma 100%
• Hypoxia 75%
• Tensin 50%
• Phosphatase 50%
• Thyroid Follicular Carcinoma 50%
• Anoxia 37%
• Enhanced Green Fluorescent Protein 25%
• Vasculotropin 25%
• Tumor Growth 12%
• Lung Metastasis 12%
• Enzyme-Linked Immunosorbent Assay 12%
• Wound 12%
• Phosphatidylinositol 3 Kinase Inhibitor 12%

Biochemistry, Genetics and Molecular Biology

• Hypoxia Inducible Factor 1 100%
• Phosphoinositide 3-Kinase 100%
• Phosphatase 66%
• Tensin 66%
• Vascular Endothelial Growth Factor 33%
• Transcription Factor 16%
• Tumor Progression 16%
• Secretion (Process) 16%
• Lactate Dehydrogenase 16%
• Phosphoinositide 3-Kinase Inhibitor 16%
• GLUT1 16%